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Background: A retrospective chart review was undertaken in a private clinic to examine the 
clinical outcomes for patients with an eating disorder comorbid with depression or bipolar 
illness who underwent a referenced electroencephalographic (EEG) database analysis to help 
guide medication selection.
Method: We examined 33 charts for patients with the primary psychiatric diagnosis of an eating 
disorder and comorbid major depressive disorder or bipolar disorder who underwent a quantita-
tive EEG database assessment to provide additional information for choices of medication. The 
current analysis includes data from 22 subjects who accepted treatments based on information 
from the referenced-EEG medication database. Hamilton Depression Rating Scale, Clinical 
Global Impression-Severity, Clinical Global Impression-Improvement, and hospitalization data 
were examined for these patients.
Results: Patients whose EEG data was used for clinical treatment reported significant decreases 
in associated depressive symptoms (HDRS scores), overall severity of illness (Clinical Global 
Impression-Severity), and overall clinical global improvement (Clinical Global Impression-
Improvement). This cohort also reported fewer inpatient, residential, and partial hospitaliza-
tion program days following referenced-EEG compared with the two-year period prior to 
treatment.
Conclusion: These findings are consistent with previously reported data for patients with eating 
disorders and suggest the need for future studies using EEG data correlated with those from 
other patients with similar quantitative EEG features.
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Introduction
The pharmacologic treatment of eating disorders has offered few options for this 
difficult-to-treat population. A large number of psychotropic medications from multiple 
drug classes have been studied as potential treatments for anorexia nervosa, but none 
has consistently proven to be efficacious.1 While one early trial reported that fluox-
etine prevented relapse in weight-restored patients with anorexia nervosa,2 multiple 
later studies, involving larger sample sizes, failed to replicate a benefit of selective 
serotonin reuptake inhibitors as a group in preventing relapse in weight-restored 
adolescents and adults with the disease.3,4 Currently, there is no drug approved by the 
US Food and Drug Administration (FDA) for the treatment of anorexia nervosa or 
eating disorder not otherwise specified (EDNOS). Only one medication, fluoxetine, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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has been approved by the FDA for the treatment of bulimia 
nervosa;5 it has been shown to decrease binging and purging 
behaviors significantly in patients with bulimia nervosa.6 
Because research has shown that eating disorders are associ-
ated with high mortality,7–10 improved pharmacotherapy is 
desperately needed.
Despite the current lack of empirically derived guidance 
for choosing medications, psychiatrists prescribe a wide 
range of psychotropic medications for patients with eating 
disorders. The high morbidity and mortality rates associ-
ated with eating disorders underscore the importance of 
finding successful and timely treatment. Frequent relapses 
and prolonged recovery periods contribute to the chronic 
nature of eating disorders.11 Compared with the general 
population, mortality rates are elevated in eating disorders. 
An examination of 6009 records spanning 30 years from the 
Swedish Cause-of-Death Register12 found that people with 
anorexia nervosa have a six-fold increase in mortality, and 
that suicide was the most frequent cause of death. In a review 
of almost two decades of records from patients evaluated at 
an outpatient eating disorders clinic,1 crude mortality rates 
were found to be 3.9% for bulimia nervosa, 4.0% for anorexia 
nervosa, and 5.2% for EDNOS. These rates were similar to 
the 5.9% rate in a study showing that the all-cause mortality 
rates for anorexia nervosa are up to 12 times higher than 
those normally seen in 15–24-year-old females and more 
than twice what is found in studies of hospitalized female 
psychiatric patients.10
Twenty-four hour supervised care is a common treat-
ment modality for patients with eating disorders. Up to 50% 
of patients with eating disorders require hospitalization for 
stabilization at some point in care.13 Inpatient hospitaliza-
tion choices remain costly and somewhat controversial, and 
the evidence for increased treatment efficacy of inpatient 
hospitalization is questionable.
The frequent comorbidity of other Axis I diagnoses 
further complicates the treatment of eating disorders. The 
rates of co-occurring mood, anxiety, and substance abuse 
in patients with eating disorders have been found to vary 
widely, depending on the methodology used and the char-
acteristics of the study sample.14 Mood disorders occur more 
frequently than anxiety disorders, and depression is the most 
common comorbid condition present. Lifetime estimates of 
depression have been reported to be as high as 88.9%.15 The 
severity of depression and anxiety symptoms was found to 
be greater in underweight patients, and lessened when weight 
was restored.16 The symptoms of mood disorders and eating 
disorders often affect one another. For example, depressive 
symptoms in adolescents predicted future bulimic eating 
pathology, which, in turn, can lead to worsening of depres-
sive symptoms.17
Without evidence-based research to support pharma-
cotherapy for eating disorders, physician choices are little 
more than educated guesses. Techniques that can successfully 
optimize pharmacotherapy by avoiding unnecessary and 
costly medication trials can benefit patients and their fami-
lies, who also suffer when their family members are ill.18 In 
addition, finding the most beneficial treatment in an efficient 
manner can serve to curb health care costs. Per patient, the 
cost of treatment for anorexia nervosa and bulimia nervosa 
have been found to be comparable with the cost of treating 
schizophrenia.19
An objective new tool that uses quantitative, normative, 
and referenced electroencephalographic (EEG) sampling 
databases can assist physicians in determining medication 
selection. This technology was pioneered in the late 1980s 
and compares drug-free quantitative EEG features for indi-
vidual patients with a database of patients with similar EEG 
patterns and with known outcomes after pharmacologic 
interventions. Based on specific EEG data elements, this 
technology can provide, before their patient begins treatment, 
quantitative EEG historic outcome data for medications likely 
to be effective, thereby reducing the need for “trial-and-error” 
prescribing. See the appendix to this paper for a detailed 
description of referenced-EEG technology.
Early studies suggested that referenced-EEGs could 
assist clinicians in finding more efficacious medications, 
especially for treatment-refractory patients. In one study, 
81 severely ill patients with anorexia nervosa, bulimia 
nervosa, or EDNOS underwent referenced-EEG analysis, 
and their medications were subsequently switched to those 
suggested by the referenced-EEG report. After 10 months, 
more than 70% of the patients with anorexia nervosa 
demonstrated weight gain and marked improvement in 
their depression   symptoms.20 In a more recent multicenter, 
randomized trial,21 referenced-EEG assisted treatment was 
compared with optimized treatment based on the STAR*D 
study guidelines funded by the National Institutes of Health22 
in patients with treatment-refractory major depressive dis-
order. Referenced-EEG assisted medication selection led 
to statistically better outcomes compared with the control 
group. The improvement in the referenced-EEG group over 
the control group was significant as early as two weeks 
after starting medications selected through referenced-EEG 
analysis, and the superior improvement continued through-
out the 12-week study.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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In order to explore further the potential of referenced-EEG 
for improving clinical outcomes when used for selecting 
pharmacotherapies in eating disorders, we performed an 
uncontrolled, retrospective chart review of clinical cases 
which used referenced-EEG in eating disorders with 
comorbid depression. We hypothesized that referenced-EEG 
assisted medication selection would improve overall clinical 
outcomes (including reducing symptoms of eating disorders 
and associated mood symptoms). This study was designed to 
evaluate referenced-EEG as an informational tool to assist 
the physician in selecting an effective medication. Because 
there are innumerable combinations of therapies available 
from the referenced-EEG report, this study was not intended 
to evaluate any one medication against another, but instead 
looks at referenced-EEG itself as a tool to improve outcomes 
after previous medication failures in this difficult population. 
It compares the referenced-EEG based therapeutic outcomes 
against the patient’s previous therapeutic outcomes prior to 
referenced-EEG, regardless of the medications being used. In 
this model, statistical differences between outcomes before 
and after referenced-EEG can be attributed to the information 
provided by referenced-EEG.
Methods
Participants
This retrospective chart review included all adolescent and 
adult patients who received a fee-for-service referenced-EEG 
at a Boston area clinic between October 10, 2003 and April 1, 
2009 and agreed to follow the medication plan derived from 
the referenced-EEG. Additionally, each participant had 
received a primary psychiatric diagnosis of an eating dis-
order (ie, anorexia nervosa, bulimia nervosa, or EDNOS) 
and had comorbid major depressive disorder or bipolar 
disorder in the depressive stage as diagnosed by a board-
certified psychiatrist. Clinical measures, both pre-referenced 
and post-referenced-EEG, included Hamilton Depression 
Rating Scale (HDRS,)23 Clinical Global Impression-Severity 
  (CGI-S)24 and Clinical Global Impression-Improvement 
(CGI-I)24 scores. The CGI evaluations were based on improve-
ment of mood as well as eating disorder symptoms. Specifi-
cally, this study investigated whether referenced-EEG assisted 
medication selection resulted in improvement of depressive 
symptoms as measured by HDRS, as well as overall clinical 
improvement measured by CGI-S and CGI-I scores.
The psychiatric clinic does not routinely collect weight 
data. All patients were monitored by their nutritionists and 
primary care physicians, who routinely weighed patients to 
assess the criterion for hospital readmission if necessary. 
Monitoring weight data for interim medication follow-up visits 
often interferes with treatment. Patients with eating disorders 
are overly focused on weight, and the potential of being 
weighed by multiple professionals in different offices is not 
standard treatment.
Hospitalization data were collected on the number of days 
of full inpatient, partial inpatient, and residential hospitaliza-
tion. Pre-referenced-EEG hospitalization data were collected 
for a period of up to two years, as recalled retrospectively by 
the patient. Post-referenced-EEG hospitalization data were 
collected for a variable period of 2–5 years. To account for 
the variability in the follow-up period, pretreatment and 
post-treatment hospitalization data were calculated as aver-
age days per month for each person. An institutional review 
board provided written approval of this retrospective chart 
review.
Data analysis
Data were extracted from the files for three intervals, ie, 
pretreatment through baseline (which corresponded to the 
referenced-EEG recording date), the clinical visit closest to 
eight weeks following the prescription of referenced-EEG 
based medications, and the visit closest to six months after 
baseline. Extracted variables included HDRS (21-item) raw 
scores, CGI-I and CGI-S scores rated by the treating profes-
sional, and hospitalization data. Hospitalization data, repre-
senting the two years prior to initiation of referenced-EEG 
assisted therapy, were drawn from the baseline session clinical 
interview in the patient’s chart, and from a background form 
completed by the patient. The treating professionals also 
reviewed the charts for the prescribed medications during 
the six months after using the referenced-EEG neurometric 
database.
Raw data were recorded on spreadsheets and changes 
in scores were calculated by subtracting the raw scores for 
eight-weekly and six-monthly visits from the baseline scores 
for HDRS, CGI-S, and CGI-I. For the CGI-I, a score of 4 (no 
change) was assigned for each person as a baseline score.
Categoric variables were also defined for the analysis as 
follows: depression response was defined as HDRS score 
improvement of 50% or more from baseline. Depression 
remission was defined as an HDRS score , 8 at any time 
post-treatment. CGI-I response was defined as scores of 1 
or 2 and CGI-I remission was defined as a score of 1 post-
treatment.
The CGI-S, CGI-I, hospitalization days, and HDRS scores 
were recorded in the chart at each visit. Additional informa-
tion obtained from the patient’s chart included   primary and Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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secondary diagnoses, age at time of referenced-EEG, history 
of failed medication trials, and previous and subsequent 
hospitalizations if available.
The CGI-S scale is a seven-point Likert scale. Clinicians 
rated the severity of a patient’s illness (in this case an eat-
ing disorder) on a scale between 1 and 7, where “1” means 
“not at all ill” and “7” means “among the most extremely 
ill” patients. The CGI-I is a similar seven-point Likert scale, 
where “1” means “very much improved”, “4” means “no 
change”, and “7” means “very much worse”. The CGI-S and 
CGI-I are well accepted outcome measures in psychiatry. 
The HDRS is a well validated depression rating scale, and 
we used the 21-item version of the HDRS to rate depressive 
symptoms, including insomnia, appetite, suicidal ideation, 
and energy level.
Hospitalizations were based upon information contained 
in the patient chart and were classified according to the level 
of care, ie, full hospitalizations, residential admissions, and 
partial hospitalizations. In the US, inpatient hospitalization 
costs were estimated to be approximately $2000 per day, and 
outpatient partial hospitalization costs were approximately 
$800 per day.25 Residential care, a level of care which fits 
between inpatient hospitalization and partial hospitaliza-
tion, is estimated to cost approximately 956 dollars/day.26 
Adjusting for inflation, these figures (in dollars/day) are 
currently estimated at $2310 inpatient hospitalization, $1033 
for residential care, and $925 for partial hospitalization. 
To determine the estimated savings, the daily costs for the 
24 months prior to referenced-EEG were calculated and the 
costs for the post-referenced-EEG care was also calculated 
and subtracted from the estimated pretreatment cost.
Given the small sample size, changes in primary variables 
(HDRS, CGI-S, and CGI-I) from baseline to eight weeks and 
six months were analyzed using the nonparametric Wilcoxon 
rank-sum (Mann–Whitney) test. Statistical significance 
was defined at the two-tailed 0.05 level. Analyses were 
performed only in the primary cohort of 22 subjects with 
eating disorders. Due to the small sample size, no analyses 
were planned or conducted for smaller population subgroups 
of anorexia nervosa (n = 11), bulimia nervosa (n = 4), or 
EDNOS (n = 7).
Results
Charts of 33 patients who elected to undergo referenced-EEG 
assessment between October 10, 2003 and April 1, 2009 were 
reviewed. Eleven patients were excluded from the analysis for 
the following reasons: seven patients decided not to follow 
the referenced-EEG-prescribed medications and withdrew 
without providing efficacy data; one patient failed to return for 
any follow-up sessions due to travel issues; two patients began 
abusing alcohol or cannabis during post-referenced-EEG treat-
ment, thereby confounding efficacy results; and one patient 
violated the pre-referenced-EEG drug washout requirement 
and was not medication-free prior to the referenced-EEG, 
rendering referenced-EEG measures invalid.
The 22 patients who received and followed referenced-
EEG-based medications averaged 24.8 ± 8.0 years of age 
(median 21.3 years). Demographic information on age, 
number of failed medications, current primary and secondary 
diagnoses, and medications used in the study are presented 
in Tables 1–3.
Patient assessment data for the eight-week time point 
averaged 59.6 ± 9.7 days, and assessment data for the 
six-month time point averaged 181 ± 12.6 days after 
prescription of medications aided by the referenced-EEG 
analysis. Most patients (n = 18) had previously failed other 
treatments during an average illness duration of 9.1 ± 7.1 
(range 1–24) years. These subjects had failed treatments 
with one or more medications (average 5.7). The failed 
therapies included 39 different medications, ranging from 
St John’s wort to haloperidol, including many of the typi-
cal medications currently being prescribed in psychiatry 
(serotonin and/or noradrenaline reuptake inhibitors, atypi-
cals, stimulants, monoamine oxidase inhibitors, lithium, 
anticonvulsants, tricyclics, and others). Four subjects 
were treatment-naïve, three of whom were aged 18 years 
or younger.
Average age of onset of eating disorders symptoms 
was 15.6 ± 5.6 years. Four (18%) were adolescents aged 
14–16 years, and 18 (82%) were adults aged 18 years or 
older. Patients had a primary diagnosis of anorexia nervosa 
(11/22, 50%), bulimia nervosa (4/22, 18%), or EDNOS 
(7/22, 32%). Each patient carried more than one   Diagnostic 
and Statistical Manual of Mental Disorders, Fourth   Edition) 
Table 1 Patient demographics by gender
Percent Overall  
n = 22
Females  
n = 21
Male  
n = 1
100% 96% 4%
Age at baseline  
(years)
Mean (sD) 24.8 (8.0) 24.2 (7.5) 39
Median 21.3 21.5 39
Age of onset of  
eD (years)
Mean (sD) 15.6 (5.6) 15.7 (5.7) 14
Median 15.8 16.0 14
Duration of  
illness (years)
Mean (sD) 9.1 (7.1) 8.3 (6.3) 25
Median 6.3 5.7 25
Number of previously  
failed medications
Mean (sD)
Median
5.7 (5.0)
4.5
5.9 (5.0)
5.0
2
2
Abbreviations: sD, standard deviation; eD, eating disorder.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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DSM-IV Axis I diagnosis. The primary comorbid diag-
nosis for each patient included either major depressive 
disorder (18/22, 82%) or bipolar disorder (4/22, 18%). 
Additionally, 12 individuals were diagnosed with comorbid 
obsessive-compulsive disorder, three with attention deficit 
disorder, five with past alcohol abuse/dependence, six with 
  generalized anxiety disorder, and one with post-traumatic 
stress disorder.
The medications that were prescribed based on review of 
the referenced-EEG report were from four different classes, 
ie, anticonvulsants, antidepressants, stimulants, and beta-
blockers (see Table 3). In this sample of patients with resistant 
eating disorders, only one was treated with a single medica-
tion (bupropion). The remainder of the patients were treated 
with combinations of medications from the four categories 
listed in the referenced-EEG report. Treatment always began 
with medications that were based on the report, ie, either 
monotherapies or combinations derived from information on 
the referenced-EEG report. In total, antidepressants were used 
in 59% of subjects, anticonvulsants in 82% of subjects, stimu-
lants in 50% of subjects, and beta-blockers in 9% of subjects. 
Due to known drug intolerance in a few patients, medications 
that were identified by name on the referenced-EEG report 
were not used. Instead, the investigator selected substitutes 
within the same drug class for the initial treatment, ie, 
duloxetine (n = 2) and oxcarbazepine (n = 3). After the initial 
treatment with referenced-EEG assisted therapies, the treating 
physician used clinical judgment to add atypical antipsychotic 
medications, which were not based on the referenced-EEG 
report (aripiprazole [n = 1] and quetiapine [n = 4]). Atypical 
antipsychotics were prescribed for additional symptom relief 
usually related to intense obsessive ruminations around food, 
weight, and/or body image. Two patients required additional 
medications that were clinically indicated to maintain sobriety 
(disulfiram, n = 1) and to treat attention deficit/hyperactivity 
disorder (guanfacine, n = 1).
hamilton Depression rating scale
Results showed a statistically significant improvement in 
HDRS scores (Table 4 and Figure 1) from pretreatment to 
both eight weeks and six months after receiving the pre-
scribed medications. Pretreatment HDRS scores ranged 
from 27 to 47, indicating that patients were suffering from 
severe depression in addition to an eating disorder. With the 
addition of pharmacotherapy guided by referenced-EEG, the 
average HDRS scores at eight weeks dropped significantly, 
although one patient remained in the severely depressed 
(24–52) range (her score dropped from 45 to 25), and five 
patients remained in the moderately depressed range (18–24 
HDRS points). Five patients reported remission of depressive 
symptoms at eight weeks (Figure 2). The balance of patients 
rated their depressive symptoms in the mild range (7–17). 
By six months, 11 patients reported complete remission 
of depression symptoms, while two remained moderately 
Table 2 Diagnoses by patient
Patient ID Primary Secondary Other axis I diagnoses
 1 BN MDD Alcohol abuse
 2 eDNOs BPD OcD
 3 BN MDD ADhD, GAD
 4 eDNOs BPD ADhD, GAD
 5 AN MDD ADhD, GAD, OcD
 6 eDNOs MDD ADhD
 7 BN MDD Alcohol abuse
 8 AN MDD GAD
 9 eDNOs MDD GAD, OcD
10 AN MDD GAD, OcD
11 AN MDD OcD
12 AN MDD OcD
13 AN MDD OcD
14 eDNOs MDD OcD
15 BN MDD OcD
16 eDNOs BPD OcD
17 AN MDD OcD, alcohol abuse
18 AN MDD OcD, alcohol dependency
19 eDNOs BPD PTsD, alcohol abuse
20 AN MDD
21 AN MDD
22 AN MDD
Abbreviations:  ADHD,  attention  deficit/hyperactivity  disorder;  AN,  anorexia 
nervosa; BPD, bipolar disorder; BN, bulimia nervosa; eDNOs, eating disorder not 
otherwise specified; GAD, generalized anxiety disorder; MDD, major depressive 
disorder;  OcD,  obsessive  compulsive  disorder;  PTsD,  post-traumatic  stress 
disorder.
Table 3 Medications selected using referenced electroence-
phalograms
Antidepressants 59% (13/22) Bupropion 23% (5/22)
Fluoxetine 9% (2/22)
Fluvoxamine 9% (2/22)
Nortriptyline 5% (1/22)
Selegiline 5% (1/22)
Sertraline 5% (1/22)
Venlafaxine 5% (1/22)
Beta-blockers 9% (2/22) Metoprolol 5% (1/22)
Atenolol 5% (1/22)
Anticonvulsants 82% (18/22) Clonazepam 14% (3/22)
Divalproex 18% (4/22)
Gabapentin 41% (9/22)
Lamotrigine 9% (2/22)
Stimulants 50% (11/22) D,L-amphetamine 18% (4/22)
D-amphetamine 5% (1/22)
Methylphenidate 27% (6/22)Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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improvement to rate. For analysis, a score of 4 (no change) was 
assigned as the CGI-I at baseline. Change, if any, was measured 
relative to that initial score. Patients in this cohort who received 
a CGI-I score of 2 or 1 (much or very much improved) were 
defined as having clinical response. The number of patients who 
responded (received a CGI-I score of 1 or 2) after eight weeks 
of treatment was 16 (73%). At six months, 20 of the 22 patients 
(91%) responded based on the CGI-I (see Figure 3).
Hospitalization data
Hospitalization  data  for  the  24  months  prior  to 
referenced-EEG assisted prescribing was available for all 
patients (Table 5). Two patients reported no psychiatric 
hospitalization prior to or after beginning referenced-EEG- 
based pharmacotherapy. In total, 18 patients (82%) had 
pre-referenced-EEG inpatient hospitalizations and only 
seven (32%) required hospitalization in the variable 2–5-
year post-referenced-EEG period. Estimated hospitalization 
cost data for the participants are shown in Figure 4. Prior 
to the referenced-EEG assisted treatment, this cohort had 
45 separate inpatient hospitalizations which accounted for 
434 days of care or 9.7 days per episode. The inpatient hos-
pitalization days of care per month for the 24 months prior 
to referenced-EEG were 0.82 days per person. The number 
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Figure 3 cGi-i response and remission.
Notes: response = cGi-i score of 1 or 2, remission – cGi-i score of 1.
Abbreviation: cGi-i, clinical Global impressions-improvement.
Table 4 Efficacy results
Baseline 8 weeks 6 months
Mean change in hDrs (sD) 39.5 (5.4) -26.7 (6.7) -30.8 (7.2)
Z score 5.684 5.685
P value ,0.0001 ,0.0001
Mean change in cGi-s (sD) 5.5 (0.6) -2.8(0.9) -3.2 (1.0)
Z score 5.745 5.812
P value ,0.0001 ,0.0001
Mean change in cGi-i (sD) -2.1 (0.8) -2.6 (0.7)
Z score 6.124 6.219
P value ,0.0001 ,0.0001
cGi-i scores of 2 or 1 (%) 16 (73%) 20 (91%)
cGi-i scores of 1 (%) 9 (41%) 15 (68%)
Notes:  statistical  analysis  used  nonparametric  two-sample  Wilcoxon  rank-sum 
(Mann–Whitney) test comparison between scores at baseline and at each of the 
two post-reference eeG time points. 
Abbreviations: hDrs, hamilton Depression rating scale; cGi-i, clinical Global 
impression-improvement; cGi-s, clinical Global impression-severity; sD, standard 
deviation.
depressed, and the remaining nine reported mild depression 
symptoms.
clinical Global impression: severity
Initial average CGI-S scores of 5.5 ± 0.6 indicate that this 
cohort was rated between 5 (markedly ill) and 6 (severely ill) 
prior to initiation of pharmacotherapy treatment. When taking 
prescribed medications guided by the referenced-EEG, the 
cohort experienced a significant reduction in CGI-S scores by an 
average of 2.8 ± 0.9 points. This took the cohort, on average, to 
a rating of between 2 (borderline mentally ill) and 3 (mildly ill). 
At six months, clinicians ratings improved again by an average 
of 3.2 ± 1.0 points, in the same range. At eight weeks, 10 of the 
22 patients were rated as 2 or 1 (mildly ill or not at all ill), and 
at six months 12 of the patients were rated as 2 or 1.
clinical Global impression: improvement
The CGI-I scores are a rating of global clinical improvement. 
CGI-I is not typically rated at baseline because there is no Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Figure 4 Estimated cost of hospitalization (2010 US dollars).
Abbreviation: Partial, Partial Hospitalization Program.
Table 5 Hospitalization days and estimated costs
Pretreatment Post-treatment
Inpatient Residential Partial Inpatient Residential Partial
Days 434 137 398 136 111 206
range 0–68 3–49 15–132 2–87 5–75 36–97
Visits 45 9 18 9 5 4
Percentage of patients 82 23 41 32 14 13
Days/person/month 0.82 0.26 0.75 0.26 0.21 0.39
cost (Us$) 1,002,540 141,521 368,150 314,160 114,663 190,550
Total (Us$) 1,512,211 612,373
Abbreviation: Partial, Partial Hospitalization Program.
of inpatient hospitalization days   post-referenced-EEG was 
reduced to 136, representing 0.26 days per person. Reduc-
tions can also be seen in residential and partial hospitaliza-
tion levels of care.
Discussion
Our retrospective chart analysis of clinical cases indicates 
that referenced-EEG may be a useful metric tool for clini-
cians making medication recommendations for refractory 
patients with eating disorders and comorbid depression or 
bipolar depression. This pilot study, in conjunction with 
previously presented work,20 suggests that further controlled 
studies of referenced-EEG are warranted in patients with 
eating disorders.
The patients who underwent referenced-EEG analysis 
in our cohort had previously failed to achieve improve-
ment with more traditional care. As these data indicate, 
referenced-EEG may be useful in selecting more effica-
cious agents in treatment-resistant patients with significant 
levels of comorbid diagnoses. When utilized in a setting 
in which the results of the referenced-EEG are integrated 
with other components of multidisciplinary treatment this 
information can be invaluable in providing effective treat-
ment to those suffering with an eating disorder and comorbid 
depression.
The results of this review are encouraging and indicate 
that treating patients with the additional information con-
veyed by referenced-EEG may result in robust treatment 
responses in a group of patients who had not previously 
responded to trial-and-error medication selection (which is 
currently considered standard practice). Some patients did 
achieve almost complete remission of their depression. Prior 
to referenced-EEG, 18 subjects (82%) required hospitaliza-
tion, but after referenced-EEG, only three of these 18 patients 
required rehospitalization within the five-year follow-up 
period in this study. These results are encouraging enough to 
suggest that the referenced-EEG may play a role in helping to 
select effective pharmacotherapy for eating disorder patients 
who have been diagnosed with comorbid major depression. 
Previously, medication trials have provided limited insight 
and guidance in the pharmacologic management of eating 
disorders.5,27–30 Many have speculated that there was no use 
for medications in the treatment of eating disorders, particu-
larly in the treatment of anorexia nervosa.5 No single class 
of medications has emerged as predictably superior for all 
individuals, suggesting that treatment according to objec-
tive neurophysiology may be more successful than by DSM 
diagnosis. Indeed, a wide range of agents was recommended 
in this study by referenced-EEG based upon the individual 
patient’s EEG. The diversity of recommended medications 
may help explain why in general the search for a single phar-
macologic agent to treat eating disorders has failed.
The medications selected from referenced-EEG 
correlations provided information that led to combinations 
from four different classes of medications. The diversity of 
medications successfully utilized in treatment of this dually 
diagnosed cohort extended beyond the drugs recommended 
by the literature in eating disorders.
Some medication recommendations were counterintui-
tive. For example, based on referenced-EEG correlations, 
stimulant medications were used in the treatment of nine 
of the 22 patients. For these nine patients, the addition of Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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a stimulant was well tolerated and associated with positive 
clinical outcomes.
The decrease in depression severity (HDRS) for these 
patients is encouraging, especially given that depression is 
frequently treatment-refractory in individuals with anorexia. 
It is intriguing that eight of the 22 patients reported an 
improvement in depression symptoms on medications that 
did not include an antidepressant. This is also consistent 
with previous research utilizing referenced-EEG in persons 
with depression.
In addition to decreasing symptoms of depression, the 
data suggest a decrease in number of hospitalizations and 
in hospitalization days. Significant cost savings were seen 
following post-referenced-EEG medication changes. As 
stated in the Methods section of the paper, after adjusting for 
inflation, the cost of treatment (in US dollars/day) per subject 
is currently estimated at $2310 for inpatient hospitalization, 
$1033 for residential care, and $925 for partial hospitaliza-
tion. This leads to a total pre-referenced-EEG treatment cost 
for these 22 subjects of $1,512,211 over the course of two 
years and a total post-referenced-EEG treatment cost of only 
$612,373 over the variable follow-up period of 2–5 years. 
The total pre-referenced-EEG cost per subject for one year 
is approximately $34,368 ($1,512,211/22 patients per two 
years). This total is within reason because the medical lit-
erature reports that the total treatment cost per patient for 
one year of treatment averages $33,105.38 Therefore the total 
post-referenced-EEG treatment cost of $27,835 per subject 
over a 2–5-year range ($612,373/22 subjects) represents a 
significant cost saving.
The potential cost savings as a result of an effective medi-
cation regimen suggests that referenced-EEG analysis may be 
cost-effective. The durability of response with medications 
selected according to data provided by the referenced-EEG, 
and the broader options of medication combinations sug-
gested by referenced-EEG analysis, portends well for advanc-
ing treatment for patients with eating disorders. People who 
elect to undergo the referenced-EEG procedure and follow 
treatment regimens based on the referenced-EEG findings 
are reporting that they are doing better overall. Because there 
are no current standard treatments for eating disorders, it 
suggests that patients are trapped in relatively long cycles 
of trial-and-error prescribing before successful therapies 
can be found.
The gender distribution in this study (21 females, one 
male) is notable. Eating disorders occur at much lower rates 
in men compared with women. In the scientific literature, 
the female to male ratio of anorexia has been reported to be 
10:1. This gender divide also exists in the prevalence rate of 
bulimia. A review of the literature39 found annual prevalence 
rates of bulimia ranging from 6.8 to 13.5 persons per 100,000 
people. The annual prevalence rate for males was reported 
as 0.8 males per 100,000 people.39 The lone male participant 
in the current study reflects the realistic proportion of men 
with eating disorders in the general population.
Furthermore, studies have indicated that there are many 
personality and clinical similarities between men with eating 
disorders and women with eating disorders.40 Also, few dif-
ferences were found in rates of comorbidity between men and 
women with eating disorders, with the exception of expected 
gender-specific differences in the rates of alcoholism and 
depression.41 This suggests that the nature of eating disorders 
is similar in both genders and the gender divide in the current 
study is of little consequence to the results.
There are several limitations inherent in this or any ret-
rospective chart review that may limit the conclusions one 
may draw from this case series. First, this review did not 
systematically document research-ready data in charts, and 
the clinic does not routinely collect weight data on patients. 
Standard clinical practice does utilize the CGI-S, CGI-I, 
and HDRS with all patients, and these data suggest both 
overall improvement and specific improvement in depres-
sion symptoms. The hospitalization data included can be 
seen as reflecting the severity of the underlying disorder 
as well as the severity of illness in these patients. Second, 
there was no comparison group in this study, so it is not clear 
what the effects of treatment would have been in a parallel 
cohort of subjects not utilizing the referenced-EEG analysis. 
However, some information is provided by comparing our 
results with pre-referenced-EEG experience (ie, treatment 
failure) and historic data for hospitalizations over the two-
year period prior to referenced-EEG. Third, this is a small 
cohort of persons who could afford the costs associated with 
the referenced-EEG and additional appointments, and thus 
these patients may not be representative of patients with eat-
ing disorders as a whole. Fourth, referenced-EEG provides 
information to physicians that helps identify medications 
based on the specific neurophysiology of each patient, ie, 
personalized medicine. These medications were utilized 
only when they were thought to be appropriate and justifi-
able. As would be expected from any tool used to augment 
decision-making in medicine, clinical judgment is critical 
in the treatment process. And fifth, although the focus of 
this study was to explore levels of depression following 
referenced-EEG-guided medication selection, the majority 
of the patients reviewed had multiple comorbid conditions Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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in addition to a diagnosis of an eating disorder and mood 
disorder. The study did not control for the presence of other 
comorbid disorders such as obsessive compulsive disorder42 
or substance abuse disorder,43 although common in this 
population. These additional comorbid conditions may have 
influenced the results of the study as they may have affected 
patient responses to the depression scales. However, to some 
degree, this may have been taken into account through the 
use of global rating scales such as the CGI-S and CGI-I. In 
conclusion, the use of referenced-EEG appears to add valu-
able information to the clinical practice of treating eating 
disorders in patients with comorbid major depressive disorder 
and bipolar disorder.
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Appendix: Reference  
electroencephalographic 
methodology
eeG collection and Z scores
The first step of the assessment is to collect 19-channel, 
awake, eyes-closed, digital electroencephalographic (EEG) 
recordings on 6–92-year-old patients who have either washed 
out their medication for five half-lives or who are currently 
medication-free. The results are reviewed in raw form by an 
electroencephalographer to ensure that no other pathology is 
present. The EEG is then screened to remove any “artifacts” 
that may exist in the EEG record. These artifacts include 
muscle twitches, eye blinks, and periods of drowsiness.
Neurometric analysis involves computation of a series of 
measures that mathematically describe the EEG. These mea-
sures are then compared with a database of “normal” EEGs. 
The software computes approximately 1200 measures derived 
from the EEG component wavelengths and amplitudes. These 
measures fall into four main categories, ie, power, coherence, 
symmetry, and frequency. Power is the sum of the amplitudes 
of the wavelengths in each band, computed on an absolute 
and relative basis. Relative power indicates the percentage 
of total power in each band. Coherence measures the syn-
chronization of electrical activity between two channels. In 
mathematical terms, coherence is the phase shift between 
similar wavelengths at the two channels. Symmetry measures 
the ratio of power between a symmetrical pair of electrodes 
and, lastly, frequency measures the average frequency of the 
EEG component wavelengths with each band.
Most neurometric features are highly non-Gaussian in 
their characteristics. For this reason, the neurometrics are 
log-transformed to make the distributions more normal 
(Gaussian) in nature. Many quantitative EEG features also 
vary consistently with age. To account for the difference 
between the age of the patient and the age of the subjects in 
the normative database, these quantitative EEG features are 
age-regressed using a linear regression equation to yield a 
“standard-age” quantitative EEG feature. The comparison 
of the actual values of the neurometric variables with norms 
is expressed as a Z score which is defined as:
Z
observed value normativemean
s dardd eviation
=
−
tan
Development of pattern variables
Neurometric analysis outputs approximately 2400 variables 
(known as univariables) that describe the EEG. To make 
this data utilizable, reference-EEG transforms this data into 
a smaller set of multivariables (or pattern variables). These 
pattern variables preserve the information contained in the 
set of quantitative EEG univariables while retaining some 
degree of physical interpretation. As such, the data are not 
simply “mined” to come up with combinations of variables 
that are indicative of one state or another; instead they are 
combined according to anatomical location. In some cases, 
factor analysis is employed to give greatest weight to those 
univariables that preserve the largest amount of total infor-
mation of all the univariables in an anatomic group. In other 
cases, the univariables in an anatomic group are combined 
in a nonlinear fashion to increase the separation of observed 
clusters within the data. At present, there are 74 pattern 
variables.
correlation of pattern variables  
with known patient outcomes
The reference-EEG variables for historical patients with 
known positive and negative clinical outcomes to various 
psychotropic medications are examined in order to develop a 
model that will allow the prospective determination of likely 
patient medication responsivity to these medications. The 
variables are examined by stratifying the distribution accord-
ing to the individual medication responsivities represented. 
Before utilizing this apparent relationship, the appropriate-
ness of the pattern variables are checked. Tests of skewness 
and kurtosis are conducted for each of the pattern variables 
to ensure that the original variable distribution is Gaussian. 
Having ensured a Gaussian distribution, mathematics can 
be applied that provide a comparison of other patients with 
similar patterns demonstrating whether the pattern variable 
value for the current test in question belongs to the distribu-
tion represented by a particular medication or belongs to the 
distribution defined by some other group (the rest of the popu-
lation). This procedure is done for all medications represented 
in the database and for all of the pattern variables that serve 
as indicators for those medications. The weightings then are 
averaged to calculate a “score” for each medication.
calibration against patient records
The final step is to calibrate this score against actual patient 
records to determine what level of score translates into a 
specified likelihood response to the medication. For purposes 
of communication, at the time of this study, three levels of 
responsiveness were created. The first is “sensitive” or “S”. 
This level indicates that the indicated medication, or group 
of medications, produced a positive outcome to treatment Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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in 80% or more of cases. “Intermediate” or “I”, the second 
level, indicates that the responsivity was in less than 80% of 
cases but more than 35% of cases. The third level, “resistive” 
or “R”, indicates that a response to the medication is seen in 
fewer than 35% of cases. In other terms, if we formulate H0 
(the null hypothesis) in such a way that H0 is true if the patient 
is not actually responsive to the medication, then the model 
is calibrated to allow for a type I error rate of no more than 
20% in the region indicated as “S” and a type II error rate of 
no more than 35% in the region designated as “R”.
To calibrate the report generator model against these 
standards, the outcomes database is queried for all patient 
responses that were not used in the construction of the actual 
model. This dataset is known as the validation sample. This 
sample is then divided into two subsets, the first of which 
is known as the tuning sample and the second is the final 
validation sample. To complete the model development, 
the scoring model is run against the tuning sample and the 
resulting distribution of scores is compared against the known 
responses. Thresholds for scores are then empirically set to 
implement the standards of S, I, and R described earlier, and 
which are common in such medical reports as, for example, 
antibiotic sensitivity results. Final validation of the model is 
made by running the processes, complete with the thresholds 
that were set, against the final validation sample. In order to 
preserve the fully prospective nature of this validation, no 
adjustment of the model parameters, including the thresholds, 
is made after this process. If the results of this “run” meet 
the specifications for the previous clinical correlations, the 
model is then ready to be used for new patients.
The reference-EEG methodology does not take into 
account the diagnosis of the patient when offering objective 
data on any specific medication. Response research has shown, 
and industry experience corroborates, that diagnosis is a poor 
predictor of the treatment most likely to be successful for the 
individual patient. This is one of the fundamental improvements 
that shared quantitative EEG features correlated to long-term 
clinical outcomes brings to the practice of psychiatry.
This process can provide objective neurophysiologic data 
to assist a physician in avoiding the unnecessary risk that 
comes with the practice of trial and error psychopharmacol-
ogy, which is also seen through the efficiency of treating a 
patient, thus reducing suffering and medical costs. The report 
is unique to each patient’s quantitative EEG features.
Previous clinical evidence
Using EEG features and patterns differs from a standard 
quantitative EEG in that it references the quantitative EEG 
to a normative and then symptomatic database. This may 
thus have the advantage of providing information about 
medication to aid in selection before treatment is initiated. 
This approach is based on correlations between particular 
EEG data and medication class response in samples of 
patients with affective and attentional symptoms.31 The 
authors extended this model by creating a database from 
patients seen in clinical practice. Since the first publication 
of this work,31 the database has continued to expand. At the 
time of the study it contained unmedicated EEGs from more 
than 1800 patients while comparing it with EEGs from a 
normative age-corrected database approved by the US Food 
and Drug Administration. For these same 1800+ patients, 
they also collected the outcomes (average length of time 
405 days) on more than 17,000 medication trials/intervals 
over time (positive, negative, or neutral) from which they built 
a usable database of 74 pattern variables. At that time, well 
over 7500 patients had accessed the correlation database. It 
provides a large collection of outcome data enabling clinical 
correlations between the patterns found in a patient’s EEG 
and a long-term treatment response to many medications. 
Small, preliminary studies have suggested a potential role in 
the use of this type of information for additional data about 
medication selection for depression, to name just one psychi-
atric disorder. A small, prospective, randomized, controlled 
study enrolled and completed 25 weeks of follow-up on 
two groups of treatment-resistant depressed patients (n = 6 
control, n = 7 experimental) at a Veterans Administration 
hospital.32 The trial used these quantitative EEG features 
to guide prescribing of psychotropic medications, while 
the control group received essential treatment as usual. The 
results indicated that six of seven subjects augmented with 
EEG data received ratings of moderate to marked improve-
ment, in contrast with a single subject in the control group. 
When unblinded, that same subject was treated successfully 
with the medication that was consistent with the EEG pat-
terns in the database. Another pilot study33 was conducted to 
compare this same methodology with the Texas Medication 
Algorithm Project34 (TMAP) algorithm for patients with 
treatment-resistant depression. This small (n = 18) 10-week 
study found that quantitative EEG variables resulted in 
statistically greater change from baseline scores for the 
Quick Inventory of Depressive Symptomatology-Self 
Report-16 (QIDS-SR16) and the Quality of Life Enjoyment 
and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) 
than TMAP-guided therapy. It also found that five subjects 
in the TMAP group received a successful TMAP therapy 
that was identical to what would have been prescribed with Neuropsychiatric Disease and Treatment
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the information obtained for the quantitative EEG features 
from the database. Recently, a larger study was conducted 
using a modified algorithm developed from the results of the 
STAR*D study as the control.21 This multicenter (12 sites) 
randomized, single-blind, controlled study of 114 treatment-
resistant subjects (89 evaluable) demonstrated significantly 
greater improvement on both primary endpoints (QIDS-SR16 
and Q-LES-Q-SF, ie, the same as in the STAR*D study) of 
P , 0.0002 compared with control, as well as statistical 
superiority in nine of 12 secondary endpoints. Pilot studies 
using these quantitative EEG variables in eating disorders20,35 
and substance abuse36,37 demonstrated similar promising 
results.